Company intelligence / Profile preview

Aronex Pharmaceuticals, Inc.

The Woodlands, Texas, United States6sense.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Aronex had several drug candidates in clinical trials, including AR-209 for Brain Cancer, Annamycin for leukemia, AR-132 for Cytomegalovirus Infections, Tretinoin Liposomal for Acute Promyelocytic Leukemia, and Liposomal NDDP for Advanced Malignant Solid Neoplasm. The company also developed AR-177, an anti-HIV drug that inhibited viral production through blocking HIV integrase.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Liposomal formulationssmall molecules
Industry: Biotech

Partnerships

Collaborations with Katholieke Universiteit LeuvenNational Cancer InstituteUniversity of California at San FranciscoSouthern Research Institute for AR-177 development

Beyond the preview

Go deeper on Aronex Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aronex Pharmaceuticals, Inc..

Explore the full profile